New Five-Year Data Shows Durable Efficacy Of AstraZeneca's Fasenra For Asthma Treatment

  • AstraZeneca Plc AZN has announced results from a new integrated analysis, including data from the MELTEMI Phase 3 open-label extension trial, evaluating Fasenra (benralizumab) in adult patients with severe asthma.
  • Results were presented today at the American Thoracic Society 2021 International Conference.
  • Data showed Fasenra was well-tolerated for up to five years, with a long-term safety profile consistent with previous Phase 3 trials.
  • During the extension trials, adverse events and serious adverse events did not increase from rates comparable to placebo observed in Phase 3 trials.
  • In secondary endpoints, Fasenra sustained the reduction in asthma exacerbation rates observed during predecessor Phase 3 trials, with annualized asthma exacerbation rates (AAER) remaining consistently low over the five-year treatment period.
  • AAER decreased from 3.1 exacerbation/year pre-treatment to 0.5 in the predecessor studies with a further reduction to 0.2 by year four of the open-label trial.
  • 59% of patients experienced zero exacerbations during the four years of the open-label period, and at least 75% of patients each year experienced zero exacerbations.
  • In the final year of the trial, 87% of patients experienced zero exacerbations.
  • Price Action: AZN shares are up 0.26% at $56.14 during the market session on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareFDAGeneralasthmaBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!